Cook Medical has released a new FDA approved venous catheter for pressure injection of CT contrast media. To prevent the occurrence of catheter-related bloodstream infections (CRBSIs), the treatment of which is no longer Medicare reimbursed, the catheter is coated with Spectrum, a proprietary formulation comprising the antibiotics minocycline and rifampin.
From the press release:
With the Spectrum Turbo-Ject PICC, clinicians can choose from multiple catheter configurations that offer an industry-best range of flow rates in order to meet patient needs, including:
Maximum pressure limit settings of 325 psi 5 French single and double lumen with a maximum flow rate of 7 and 5 mL/second, respectively 4 French single lumen with a maximum flow rate of 4 mL/second 50 cm and 60 cm length available Spectrum technology has been shown to establish zones of inhibition greater than 15 mm for up to 63 days against the leading cause of CRBSIs.
The combination of the antibiotics minocycline and rifampin that are impregnated within the material of the Cook Spectrum catheters work synergistically to provide broad-spectrum protection against gram positive, gram negative and fungal organisms in both short- and long-term use. Unlike most systemic antibiotics, this unique combination has the ability to penetrate the biofilm that forms on all indwelling catheters. Additionally, research has conclusively shown that use of these catheters does not promote the growth of antibiotic-resistant strains of bacteria in patients receiving Spectrum catheters. In fact, the use of Spectrum technology has demonstrated reduced antibiotic-resistant strains in on single-center study.
The Cook Spectrum Turbo-Ject PICC will be complimented by the PICC Procedural Tray, designed to efficiently supply the essential components for a clinician placing a PICC, whether bedside or in an interventional radiology lab. The tray provides the vital components for maximal sterile barrier precautions, a significant part of patient safety and infection control.
Medgadget is thrilled to announce that a couple of your editors will be attending and covering TEDMED this October 27-30th on the beautiful Coronado Island, off the coast of San Diego. If you’ve not heard about TEDMED already, it’s pretty much the ultimate conference for those interested in medical advances. Created by Marc Hodosh (from the Archon X PRIZE for Genomics) in partnership with Richard Saul Wurman (TED founder), the forum is short speeches with plenty of time for networking in order to, according to their website, “celebrate conversations that demonstrate the intersection and connection between all things medical and healthcare related.” Speakers include the likes of Dean Kamen, Craig Venter, Sanjay Gupta, Anne Wojcicki, and 
Edwards Lifesciences won FDA approval for its new Carpentier-Edwards PERIMOUNT Magna Ease aortic valve, and is also introducing the PORT ACCESS EndoDirect surgery system for minimally invasive cardiac procedures.
Understanding the state of the intracranial environment is important in patients following traumatic brain injury. Researchers at the University of Cincinnati have created a “lab-on-a-tube” device that can drain cerebrospinal fluid (CSF) while monitoring the pressure, oxygen content, temperature, and glucose within the intracranial space. The researchers describe the new device that uses sensors wrapped into a helix in the March 20th issue of Lab on a Chip.
Damaged cartilage of large bones, as in osteoarthritis, is a particularly common condition in humans, especially as we age. Now there’s hope that cartilage grafts may be possible thanks to fiber scaffolds with nano scale features.
The FDA has given St. Jude Medical approval for the Attune Flexible Adjustable Annuloplasty Ring. Indicated for patients with mitral regurg, the product’s unique adjustable design should let the surgeon perform a tighter, more precise fitting.
